<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634192</url>
  </required_header>
  <id_info>
    <org_study_id>CTBM100DDE01</org_study_id>
    <nct_id>NCT00634192</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin</brief_title>
  <official_title>A Multicenter, Open Label, 2 Period Cross-over Study to Evaluate the PK of a 8 Week Continuous Treatment With 1x300mg/d and 2x300mg/d Tobramycin Inhaled With a 'Soft Mist' Nebulizer in Cystic Fibrosis (CF) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to provide data about the pharmacokinetics (PK), safety and&#xD;
      tolerability of two continuous treatment regimes of tobramycin nebulized solution delivered&#xD;
      via a 'soft mist' nebulizer in Cystic Fibrosis (CF) subjects. Each treatment period will last&#xD;
      8 weeks. Additionally the PK of patients with a normal forced expiratory flow in 1 second&#xD;
      (FEV1) (FEV1≥80% predicted) will be compared to patients with an abnormal FEV1 (FEV1&lt;80%&#xD;
      predicted).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the serum pharmacokinetics (PK) of inhaled tobramycin (AUC 0-90') of continuous daily dosing regimens with 2x300mg/d Tobramycin Nebuliser Solution (=TNS) inhaled with the PARI eFlow® rapid in Cystic Fibrosis (CF) subjects</measure>
    <time_frame>8 wks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum PK of inhaled tobramycin (AUC 0-90') of continuous daily dosing regimens with 1 x 300mg/d tobramycin nebulized solution (= TNS) inhaled with the PARI eFlow rapid in cystic fibrosis subjects.</measure>
    <time_frame>8 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare serum PK of inhaled tobramycin (trough-/peak-level)of both dosing regimens in CF-subjects with a FEV1≥80% vs. CF-Subjects with a FEV1&lt;80%.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of MIC of P. aeruginosa during a continuous treatment with 1 x 300 mg/d and 2 x 300 mg/d TNS.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess safety of a continuous daily dosing regimen with 1 x 300 mg/d and 2 x 300 mg/d TNS over 8 weeks, compared to historic safety data of the 4 week on/off dosing regimen with 2 x 300 mg/d.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pseudomonas Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tobramycin</intervention_name>
    <description>1x300mg/d inhaled</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tobramycin</intervention_name>
    <description>2x300mg/d inhaled</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects aged ≥6 years at the time of screening, with an Informed&#xD;
             Consent Form signed by patient and if appropriate by parent/legal guardians, prior to&#xD;
             any study-related procedure.&#xD;
&#xD;
          -  Confirmed diagnosis of CF by the presence of one or more clinical features of CF in&#xD;
             addition to a quantitative pilocarpine iontophoresis sweat chloride test of &gt;60 mEq/L;&#xD;
             or identification of well-characterized disease-causing mutations in each CFTR gene;&#xD;
             or an abnormal nasal transepithelial potential difference characteristic of CF.&#xD;
&#xD;
          -  P aeruginosa must be present in sputum or deep throat swab (or bronchoalveolar lavage&#xD;
             [BAL]) at the screening visit and within 6 months prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of sputum (or BAL) culture yielding Burkholderia cepacia (B cepacia) within 2&#xD;
             years prior to screening and/or sputum culture yielding B cepacia at screening.&#xD;
&#xD;
          -  FEV1 &lt;25% of normal predicted values for age, sex, and height based on Knudson&#xD;
             criteria at screening.&#xD;
&#xD;
          -  Hemoptysis of more than 60 cc at any time within 30 days prior to study drug&#xD;
             administration.&#xD;
&#xD;
          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.&#xD;
&#xD;
          -  GFR&lt;60ml/min/1.73m2 calculated with the Formula by Schwartz, BUN 40 mg/dl or more, or&#xD;
             an abnormal urinalysis defined as 2+ or greater proteinuria.&#xD;
&#xD;
          -  History of tinnitus or pathologic audiometry&#xD;
&#xD;
          -  diagnosis of Allergic bronchopulmonary aspergillosis (ABPA) at screening&#xD;
&#xD;
          -  Initiation of treatment with macrolide antibiotics within 28 days prior to study drug&#xD;
             administration (subjects may be taking macrolide antibiotics at the time of&#xD;
             enrollment, but they must have initiated treatment at least 28 days prior to study&#xD;
             drug administration).&#xD;
&#xD;
          -  Use of loop diuretics within 7 days prior to study drug administration.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharma AG</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator site</name>
      <address>
        <city>Halle/Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Koeln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>van Koningsbruggen-Rietschel S, Heuer HE, Merkel N, Posselt HG, Staab D, Sieder C, Ziegler J, Krippner F, Rietschel E. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients. J Antimicrob Chemother. 2016 Mar;71(3):711-7. doi: 10.1093/jac/dkv399. Epub 2015 Nov 30.</citation>
    <PMID>26626719</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>March 4, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic infection with P. aeruginosa in Cystic Fibrosis subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

